Mechanisms of antifungal agent resistance

Journal of Microbiology, Immunology and Infection

Volumn 34, Issue 2, 2001, Pages 79-86

  Yang, Y L ^a   Lo, H J ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Antifungal agent; Drug resistance; Fungal infection; Molecular mechanism

Indexed keywords

ANTIFUNGAL AGENT; FLUCYTOSINE; POLYENE;

CHROMOSOME NUMBER; CROSS RESISTANCE; DISEASE RESISTANCE; DRUG MECHANISM; DRUG TARGETING; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; REVIEW;

ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CHROMOSOMES, FUNGAL; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENES, MDR; MEMBRANE TRANSPORT PROTEINS;

EID: 0034947444     PISSN: 02532662     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
2. Molecular mechanisms of drug resistance in fungi
3. High prevalence of antifungal resistance in Candida spp. from patients with AIDS
4. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation
5. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993
6. High-performance liquid chromatographic determination of amphotericin B in a liposomal pharmaceutical product and validation of the assay
7. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats
8. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors
9. New aspects in treatment of systemic mycoses
10. Antifungal agents in the 1990s: Current status and future developments
11. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
12. Molecular mechanisms of azole resistance in fungi
13. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition
14. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents
15. Sequence of the Candida albicans erg7 gene
16. Nucleotide sequence of cytochrome P-450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans
17. Mechanism of fluconazole resistance in Candida krusei
18. Emergency of fluconazole-resistant infections by Candida krusei and Candida glabrata in neutropenic patients
19. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole
20. Mycoses caused by Candida lusitaniae
21. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
22. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission
23. Differential effects of changes in the length of a signal/anchor domain on membrane insertion, subunit assembly, and intracellular transport of a type II integral membrane protein
24. Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents
25. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals
26. ABC transporters: From microorganisms to man
27. Ins and outs of antimicrobial resistance: Era of the drug pumps
28. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
29. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
30. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
31. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
32. Expression of drug efflux-associated genes and multidrug resistance in Candida albicans
33. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate
34. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene
35. Activation of the multiple drug resistance gene MDR1 in fluconazole-resistant, clinical Candida albicans strains is caused by mutations in a trans-regulatory factor
36. CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole
37. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR
38. Cloning and characterization of ERG25, the Saccharomyces cerevisiae gene encoding C-4 sterol methyl oxidase
39. Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae
40. Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents
41. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation
42. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 alpha demethylase in Candida albicans
43. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents
44. Mechanisms and clinical impact of antifungal drug resistance
45. Antifungal resistance trends towards the year 2000: Implications for therapy and new approaches
46. Polyene resistance in ergosterol producing strains of Candida albicans
47. Antimicrobial agents. XXI. Dependence of antifungal activity on the structure of the side chain in the pyrimidine group
48. Incidence of polyene-resistant yeasts recovered from clinical specimens
49. Sterol biosynthesis in antibiotic-resistant yeast: Nystatin
50. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes
51. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans
52. Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy
53. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata
54. Monosomy of a specific chromosome determines L-sorbose utilization: A novel regulatory mechanism in Candida albicans
55. Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans
56. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis
57. Current and emerging azole antifungal agents